Literature DB >> 11147223

Insights into the biologic and molecular abnormalities in adult acute lymphocytic leukemia.

S Faderl1, M Albitar.   

Abstract

The last 3 decades have seen much progress in the treatment and outcome of patients with ALL. Unfortunately, the success that has been achieved in children with ALL has not yet been translated into adult patients. Insight into the biologic and molecular abnormalities in ALL may, however, provide the necessary clues that allow a clearer understanding of the crucial differences in the behavior of ALL in different groups of patients. As the molecular basis of the disease is deciphered, new targets are discovered that may prove useful for therapeutic interventions in the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147223     DOI: 10.1016/s0889-8588(05)70186-6

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  4 in total

1.  Immunophenotypes and outcome of Philadelphia chromosome-positive and -negative Thai adult acute lymphoblastic leukemia.

Authors:  Chirayu Udomsakdi-Auewarakul; Orathai Promsuwicha; Chintana Tocharoentanaphol; Chanya Munhketvit; Kovit Pattanapanyasat; Surapol Issaragrisil
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 2.  Adult acute lymphoblastic leukemia: concepts and strategies.

Authors:  Stefan Faderl; Susan O'Brien; Ching-Hon Pui; Wendy Stock; Meir Wetzler; Dieter Hoelzer; Hagop M Kantarjian
Journal:  Cancer       Date:  2010-03-01       Impact factor: 6.860

Review 3.  Diagnosis and subclassification of acute lymphoblastic leukemia.

Authors:  Sabina Chiaretti; Gina Zini; Renato Bassan
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-11-01       Impact factor: 2.576

Review 4.  The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy.

Authors:  Chengxin Luan; Zixue Yang; Baoan Chen
Journal:  Onco Targets Ther       Date:  2015-10-13       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.